Malvern, Pennsylvania, United States Cephalon appeared to be the Corporate Investor, which was created in 1987. The venture was found in North America in United States. The main office of represented Corporate Investor is situated in the Malvern.
The fund is constantly included in less than 2 investment rounds annually. The increased amount of exits for fund were in 2011. Deals in the range of 10 - 50 millions dollars are the general things for fund. The top activity for fund was in 2011.
The usual cause for the fund is to invest in rounds with 2 partakers. The meaningful sponsors for the fund in investment in the same round are Novo Nordisk, MacAndrews & Forbes, Incorporated. In the next rounds fund is usually obtained by Whiz Partners, National Institutes of Health, Forest Laboratories.
The current fund was established by Noubar Afeyan.
For fund there is no match between the location of its establishment and the land of its numerous investments - Japan. Among the most popular portfolio startups of the fund, we may highlight SymBio Pharmaceuticals, TransTech Pharma. Among the most successful fund investment fields, there are Health Care, Pharmaceutical. The fund has specific favorite in a number of founders of portfolio startups. Besides, a startup requires to be at the age of 4-5 years to receive the investment from the fund.
| Fund Name | Location |
| First Star Ventures | Boston, Massachusetts, United States |
| FoodFutureCo | New York, New York, United States |
| Konvoy Ventures | Colorado, Denver, United States |
| KuE Capital | Ciudad Valles, Mexico, San Luis Potosi |
| m2f investment | Germany, North Rhine-Westphalia, Recklinghausen |
| Mohawk Ventures | - |
| NCPDP | Arizona, Scottsdale, United States |
| Onevest | New York, New York, United States |
| Technology & Innovation Fund | New Jersey, Toms River, United States |
| Zhengyou Asset | China, Ningbo Shi, Zhejiang |
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data 